| scholarly article | Q13442814 |
| P50 | author | Charles Erlichman | Q107069384 |
| P2093 | author name string | C David James | |
| Jann N Sarkaria | |||
| Ravi D Rao | |||
| Ann C Mladek | |||
| Jeffrey D Lamont | |||
| Jennie M Goble | |||
| P2860 | cites work | Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 |
| Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism | Q24603034 | ||
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. | Q27824772 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells | Q28191714 | ||
| Integration of growth factor and nutrient signaling: implications for cancer biology | Q28208399 | ||
| Hierarchical phosphorylation of the translation inhibitor 4E-BP1 | Q28363125 | ||
| Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis | Q28593435 | ||
| Integration of Growth Factor and Nutrient Signaling | Q29395218 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression | Q29617473 | ||
| eIF4E activity is regulated at multiple levels | Q33601634 | ||
| Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo | Q33942901 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin | Q34114303 | ||
| Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention | Q34595904 | ||
| Epidermal growth factor receptor inhibitors in clinical development | Q35669152 | ||
| Signaling control of mRNA translation in cancer pathogenesis | Q35750101 | ||
| Oncogenic growth factor receptors: implications for signal transduction therapy | Q35818569 | ||
| Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents | Q35971876 | ||
| Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. | Q40469450 | ||
| Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. | Q40505812 | ||
| The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites | Q40756366 | ||
| A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. | Q40875073 | ||
| Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis | Q40952877 | ||
| Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor | Q42799161 | ||
| Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo | Q44462995 | ||
| Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. | Q45004003 | ||
| Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
| dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. | Q52594512 | ||
| PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. | Q55474170 | ||
| Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. | Q55475915 | ||
| Ras activation in astrocytomas and neurofibromas. | Q55477300 | ||
| A monoclonal antibody to the human epidermal growth factor receptor | Q72695320 | ||
| Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor | Q73322106 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 921-9 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells | |
| P478 | volume | 7 |
| Q33401450 | A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors |
| Q30301096 | A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K |
| Q28389391 | A review of the past, present, and future directions of neoplasia |
| Q53079070 | AKT kinase pathway: a leading target in cancer research |
| Q46024830 | Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. |
| Q38265614 | Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma |
| Q21133610 | Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model |
| Q48470503 | Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ |
| Q37809861 | Current and emerging molecular targets in glioma |
| Q39736362 | Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells |
| Q39251444 | Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors |
| Q33604979 | Enhancing mTOR-targeted cancer therapy |
| Q29615474 | Epidermal growth factor receptor mutations in lung cancer |
| Q34966112 | Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells |
| Q34735661 | Glial progenitors as targets for transformation in glioma |
| Q35238064 | Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. |
| Q33683844 | Identifying disease-associated pathways in one-phenotype data based on reversal gene expression orderings |
| Q36764876 | Inhibiting kinases in malignant gliomas |
| Q36494138 | Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q36600294 | Investigating mammalian target of rapamycin inhibitors for their anticancer properties |
| Q24619748 | Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression |
| Q38089834 | Malignant glioma drug discovery – targeting protein kinases |
| Q36778676 | Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. |
| Q36829847 | Molecularly targeted therapy for malignant glioma |
| Q37974367 | Molecularly targeted therapy in neuro-oncology |
| Q37457873 | NF-kappaB and STAT3 signaling in glioma: targets for future therapies |
| Q46932476 | Neoplasia: An Anniversary of Progress |
| Q28395095 | Neoplasia: Where We Have Been and Where We Are Going |
| Q35882200 | Netrin-4 promotes glioblastoma cell proliferation through integrin β4 signaling |
| Q96950415 | Overcoming cancer therapeutic bottleneck by drug repurposing |
| Q37389181 | Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy |
| Q37808385 | PI3Kinase signaling in glioblastoma |
| Q33747609 | Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma |
| Q33396953 | Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors |
| Q37641248 | Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 |
| Q54504827 | Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. |
| Q33578960 | Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models |
| Q37444920 | Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. |
| Q35914525 | Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo |
| Q37950771 | Rapamycin passes the torch: a new generation of mTOR inhibitors |
| Q35757208 | Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q91646021 | Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential |
| Q37487158 | Resistance mechanisms of tumour cells to EGFR inhibitors |
| Q39057993 | Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation |
| Q37761935 | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics |
| Q37736255 | Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma |
| Q37132788 | Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives |
| Q36742629 | Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations |
| Q38699320 | Targeting translation: eIF4E as an emerging anticancer drug target |
| Q35864082 | The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas |
| Q36485266 | The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas |
Search more.